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Update of a systematic review of
vitamin D for preventing osteoporotic
fractures
Osteoporotic fractures are a major and
growing healthcare problem in many
industrialised societies. An epidemiologi-
cal study of fracture data between 1988
and 1998 for England and Wales found
that one in two women and one in five
men over the age of 50 had suffered a
fracture.1 Most of these fractures would
have occurred after low-energy trauma,
such as a fall from standing height or less,
in bone weakened by osteoporosis. Of the
fractures primarily associated with osteo-
porosis, hip fracture is the most disabling
and is often fatal. Mainly old (mean age
,80 years), female (,80% are women)
and often frail people sustain hip frac-
tures. Characteristically such people have
insufficient vitamin D, which is a key
agent for building bone. An update of a
comprehensive systematic review that
examines the effects of vitamin D and
vitamin D analogues for preventing osteo-
porotic fractures in older people has been
published in the Cochrane Database of
Systematic Reviews.2
This review by Avenell and colleagues
includes 45 trials, of which, 42 were
individually randomised trials, one was a
large cluster randomised trial, and two
were quasi-randomised. On the basis of
predefined objectives established in pre-
vious versions of the review, the authors
present the results for fractures separately
for different comparisons and overall for
adverse effects (hypercalcaemia, renal dis-
ease, gastrointestinal symptoms and
death). Subgroup analyses by residential
status (community dwelling versus insti-
tutional care) and history of previous
osteoporotic fracture were also per-
formed. The results for the two main
comparisons, vitamin D alone versus
control and vitamin D plus calcium versus
control, are summarised below.
Pooled data from nine trials, and 24 749
participants, consistently showed that
vitamin D alone did not prevent hip
fracture (relative rate (RR) 1.15, 95% CI
0.99 to 1.33). A similar lack of protective
effect was evident from the available data
for non-vertebral fracture (all fractures
except those of the vertebrae), vertebral
fracture (clinically evident fracture or new
vertebral deformity on a radiograph) and
any new fracture (fractures from studies
that did not report by fracture location).
In contrast, pooled data from eight
trials, and 46 658 participants, showed
that vitamin D with calcium significantly
reduced hip fracture (RR 0.84, 95% CI
0.73 to 0.96). These results were statisti-
cally homogeneous. In their subgroup
analysis by residential status, Avenell et
al reported that, although these showed a
significant reduction of hip fractures in
people in institutional care (data from
two trials conducted by the same inves-
tigators in France), the difference between
this and a community-dwelling subgroup
was not significant (p = 0.15). Thus a
greater effect in the institutional sub-
group is not proven. Nonetheless, as the
authors reflect, a greater benefit from
administration of vitamin D and calcium
would be consistent with data from
clinical biochemistry and epidemiology
that reveal that many frail institutiona-
lised older people are vitamin D deficient,
especially in the winter months. The
pooled results for non-vertebral and ver-
tebral fractures were not significant.
Avenell et al found that vitamin D or
vitamin D analogues, with or without
calcium, significantly increased hypercal-
caemia (high blood calcium), gastrointest-
inal symptoms and renal disease.
Although these risks were relatively small,
the risk of hypercalcaemia was particu-
larly high with calcitrol, a vitamin D
analogue. Although vitamin D did not
reduce overall mortality, the authors
observed that the marginal reduction in
risk of death in people receiving vitamin D
with calcium is consistent with the
reduction in hip fracture risk.
On the basis of the available evidence,
the authors concluded that taking vitamin
D alone is unlikely to prevent fracture.
However, vitamin D taken with addi-
tional calcium supplements does appear
to reduce hip fracture, particularly in
people living in institutional care. The
authors advised caution for some people,
such as those with kidney disease or high
blood calcium, and emphasised that there
was a particularly high risk of hypercal-
caemia with calcitrol. The full review,
which also presents results for other
comparisons tested involving vitamin D
and vitamin D analogues, is available in
the Cochrane Database of Systematic
Reviews.2
The maintenance of Cochrane reviews
in the light of new evidence and develop-
ments is one of the key attributes of and
aspirations for these reviews. The citation
of an updated Cochrane review may
remain unchanged, as for this review,
because the criteria for citation change,
including substantively changed conclu-
sions, have not been met. It remains an
important observation, however, that
there were no important changes to the
conclusions regarding fracture prevention
despite the addition of eight new trials,
contributing data from 44 827 partici-
pants who were mainly community
dwellers. This brought the total to
84 585 participants for the review.
As the authors make clear, this abun-
dance of evidence does not preclude the
need for further primary research or,
indeed, another review update in due
course. In particular, a case could be made
for large multi-centre placebo-controlled
randomised trials of vitamin D with
calcium in institutional settings in differ-
ent countries. Such trials need to be
informed by vitamin D dose-finding stu-
dies.
The review highlighted in this article is
registered with the Cochrane, Bone, Joint
and Muscle Trauma Group (www.bjmtg.
cochrane.org). The work of this group
involves preparing, maintaining and pro-
moting the accessibility of systematic
reviews on different aspects of the
prevention, treatment and rehabilitation
of musculoskeletal injuries. People inter-
ested in contributing to this work can
contact Lindsey Elstub, the Review
Group Coordinator, at lindsey.elstub@
manchester.ac.uk.
H Handoll
Correspondence to: Dr H Handoll, Centre for
Rehabilitation Sciences, School of Health and Social
Care, University of Teesside, Middlesbrough TS1 3BA,
UK; h.handoll@tees.ac.uk
Competing interests: None.
Injury Prevention 2009;15:213.
doi:10.1136/ip.2009.021576
REFERENCES
1. van Staa TP, Dennison EM, Leufkens HG, et al.
Epidemiology of fractures in England and Wales. Bone
2001;29:517–22.
2. Avenell A, Gillespie WJ, Gillespie LD, et al. Vitamin D
and vitamin D analogues for preventing fractures
associated with involutional and post-menopausal
osteoporosis. Cochrane Database Syst Rev
2005;(3):CD000227.
Cochrane corner
Injury Prevention June 2009 Vol 15 No 3 213
 group.bmj.com on February 15, 2010 - Published by injuryprevention.bmj.comDownloaded from 
